Ublituximab

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma

Trial Timeline

Jul 19, 2012 → May 1, 2015

NCT ID

NCT01647971

About Ublituximab

Ublituximab is a phase 1/2 stage product being developed by TG Therapeutics for Non-Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01647971. Target conditions include Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06864936	Pre-clinical	Recruiting	Jan 1, 2026	Jun 30, 2027	Multiple Sclerosis (MS) - Relapsing-remitting
NCT07225361	Approved	Recruiting	Nov 28, 2025	Aug 1, 2029	Multiple Sclerosis
NCT04130997	Phase 3	Active	Nov 18, 2019	May 31, 2032	Relapsing Multiple Sclerosis (RMS)
NCT03381170	Phase 2	Completed	Jun 1, 2017	Nov 11, 2022	Relapsing Remitting Multiple Sclerosis
NCT01647971	Phase 1/2	Completed	Jul 19, 2012	May 1, 2015	Non-Hodgkins Lymphoma

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Acalabrutinib + ACP-319	AstraZeneca	Phase 1/2	32
JBH492	Novartis	Phase 1	21
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C	Roche	Phase 1/2	36
Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin	Roche	Phase 2	42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab	Amgen	Phase 2	35
hLL2 (epratuzumab)	Gilead Sciences	Phase 1	21
Velcade + Temsirolimus	Pfizer	Phase 2	35
alemtuzumab	Sanofi	Phase 1/2	24
Odronextamab + REGN5837	Regeneron Pharmaceuticals	Phase 1	36
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine	Bayer	Phase 1/2	25
Rituximab + Fludarabine + CAMPTH-1H	Bayer	Phase 2	32
Rituximab + CHOP + CVP + Ibritumomab Tiuxetan	Biogen	Phase 2	32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y Zevalin	Biogen	Phase 2	32
Ublituximab + Lenalidomide	TG Therapeutics	Phase 1	18
XmAb13676	Xencor	Phase 1	23